Celyad - Model CYAD-211 - Allogeneic CAR T Candidate

CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a single shRNA hairpin which interferes with the expression of the CD3ζ component of the TCR complex. CYAD-211 is currently being evaluated, following Cyflu chemotherapy, in the Phase 1 IMMUNICY-1 trial for the treatment of relapsed/refractory multiple myeloma.